Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 3/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | CASP1 | P29466 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20719835 | 0.77 | SQOR (0.31) | — | |
| SCHEMBL17477901 | 0.75 | CCR4 (0.41) | PDCD1LG2CD274MERTKCRHBPCRHR2 | |
| SCHEMBL20719730 | 0.73 | PDCD1LG2 (0.34) | PDCD1LG2CD274MERTKCRHBPCRHR2 | |
| SCHEMBL16617001 | 0.72 | ABCB11 (0.35) | L3MBTL1PDCD1LG2CD274KDM4EMEN1 | |
| SCHEMBL16617494 | 0.72 | PLCG1 (0.34) | L3MBTL1PDCD1LG2CD274MEN1MAPT | |
| SCHEMBL3508448 | 0.70 | CD274 (0.37) | L3MBTL1PDCD1LG2CD274MERTKCRHBP | |
| SCHEMBL20719250 | 0.69 | TSHR (0.37) | L3MBTL1PDCD1LG2CD274SMN1; SMN2MEN1 | |
| SCHEMBL2176428 | 0.68 | L3MBTL1 (0.58) | L3MBTL1MERTKCRHBPCRHR2ALDH1A1 | |
| SCHEMBL29983776 | 0.68 | L3MBTL1 (0.58) | L3MBTL1MERTKCRHBPCRHR2ALDH1A1 | |
| SCHEMBL20719692 | 0.68 | PDCD1LG2 (0.43) | L3MBTL1PDCD1LG2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590083-B2 | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-17 | — | — | US | disclosed |
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-03 | — | — | US | disclosed |
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-02 | — | — | US | disclosed |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047959-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | L3MBTL1 4824/4885AR 2183/4885PDCD1LG2 4328/4885 |
| US-10590083-B2 | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | L3MBTL1 4810/4885AR 2262/4885PDCD1LG2 4342/4885 |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | L3MBTL1 4824/4885AR 2183/4885PDCD1LG2 4328/4885 |
| US-20190047959-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | L3MBTL1 4810/4885AR 2262/4885PDCD1LG2 4342/4885 |
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | L3MBTL1 4815/4885AR 2208/4885PDCD1LG2 4357/4885 |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | L3MBTL1 4815/4885AR 2208/4885PDCD1LG2 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.